Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**acetaminophen + butalbital** is an oral pharmaceutical combination of two small molecules: acetaminophen, an analgesic and antipyretic, and butalbital, a short-to-intermediate acting barbiturate. It is primarily indicated for the symptomatic treatment of **tension-type (muscle contraction) headaches** when other non-opioid analgesics and alternative treatments are inadequate[3][6][8]. Acetaminophen alters the way the body senses pain, likely through central inhibition of prostaglandin synthesis and modulation of serotonergic pathways, although its precise analgesic mechanism is not fully understood[3][7]. Butalbital is a central nervous system depressant that acts as a positive allosteric modulator at the GABA(A) receptor and can also antagonize certain neuronal acetylcholine and glutamate receptors, providing sedative and muscle-relaxing effects[1]. Butalbital is habit-forming, with risk of dependence, tolerance, and withdrawal. The use of this combination is limited due to potential for medication overuse headaches, CNS depression, abuse, and acetaminophen-related hepatotoxicity at high doses. The product is available as branded and generic oral tablets and capsules[6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + butalbital.